Publikationen

Medizin 1

Direktor:
Prof. Dr. med. Markus F. Neurath

Arbeitsgruppe Therapeutische Immunsuppression: Molekulare Mechanismen und experimentelle Strategien

Publikationen

2017

Wiesinger M, Stoica D, Roessner S, Lorenz C, Fischer A, Atreya R, Neufert CF, Atreya I, Scheffold A, Schuler-Thurner B, Neurath MF, Schuler G, Voskens CJ. Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders. Front Immunol. 2017 Oct 26;8:1371. doi:10.3389/fimmu.2017.

López-Posadas R, Stürzl M, Atreya I, Neurath MF, Britzen-Laurent N. Interplay of GTPases and Cytoskeleton in Cellular Barrier Defects during Gut Inflammation. Front Immunol. 2017 Oct 5;8:1240. doi: 10.3389/fimmu.2017.01240.

Zundler S, Klingberg A, Schillinger D, Fischer S, Neufert C, Atreya I, Gunzer M, Neurath MF. Three-Dimensional Cross-Sectional Light-Sheet Microscopy Imaging of the Inflamed Mouse Gut. Gastroenterology. 2017 Oct;153(4):898-900.

Fuchs F, Schillinger D, Atreya R, Hirschmann S, Fischer S, Neufert C, Atreya I, Neurath MF, Zundler S. Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles. Front Immunol. 2017 Jul 3;8:764. doi: 10.3389/fimmu.2017.00764.

Voskens CJ, Fischer A, Roessner S, Lorenz C, Hirschmann S, Atreya R, Neufert C, Atreya I, Neurath MF, Schuler G. Characterization and Expansion of Autologous GMP-ready Regulatory T Cells for TREG-based Cell Therapy in Patients with Ulcerative Colitis. Inflamm Bowel Dis. 2017 Aug;23(8):1348-1359.

Zundler S, Fischer A, Schillinger D, Binder MT, Atreya R, Rath T, Lopez-Pósadas R, Voskens CJ, Watson A, Atreya I, Neufert C, Neurath MF. The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo. Inflamm Bowel Dis. 2017 Mar;23(3):379-391.

López-Posadas R, Neurath MF, Atreya I. Molecular pathways driving disease-specific alterations of intestinal epithelial cells. Cell Mol Life Sci. 2017 Mar;74(5):803-826.

Atreya I, Neurath MF. Microbiota: relevant player in thiopurine metabolisation? Gut. 2017 Jan;66(1):1-3.

Zundler S, Schillinger D, Fischer A, Atreya R, López-Posadas R, Watson A, Neufert C, Atreya I, Neurath MF. Blockade of αEβ7 integrin suppresses accumulation of CD8(+) and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo. Gut. 2017 Nov; 66(11):1936-1948.

2016

Atreya I, Diall A, Dvorsky R, Atreya R, Henninger C, Grün M, Hofmann U, Schaeffeler E, López-Posadas R, Daehn I, Zenker S, Döbrönti M, Neufert C, Billmeier U, Zundler S, Fritz G, Schwab M, Neurath MF. Designer Thiopurine-analogues for Optimised Immunosuppression in Inflammatory Bowel Diseases. J Crohns Colitis. 2016 Oct;10(10):1132-43.

López-Posadas R, Becker C, Günther C, Tenzer S, Amann K, Billmeier U, Atreya R, Fiorino G, Vetrano S, Danese S, Ekici AB, Wirtz S, Thonn V, Watson AJ, Brakebusch C, Bergö M, Neurath MF*, Atreya I*. Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation. J Clin Invest. 2016 Feb;126(2):611-26. (*Authors contributed equally).

Fischer A, Zundler S, Atreya R, Rath T, Voskens C, Hirschmann S, López-Posadas R, Watson A, Becker C, Schuler G, Neufert C*, Atreya I*, Neurath MF*. Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. Gut. 2016 Oct;65(10):1642-64. (*Authors contributed equally).

2015

Meinhardt K, Kroeger I, Bauer R, Ganss F, Ovsiy I, Rothamer J, Büttner M,  Atreya I, Waldner M, Bittrich M, Lehmann CH, Rieger MA, Beilhack A, Zeiser R, Edinger M, Dudziak D, Mackensen A, Rehli M, Ullrich E. Identification and characterization of the specific murine NK cell subset supporting graft-versus-leukemia- and reducing graft-versus-host-effects. Oncoimmunology. 2015 Feb 3;4(1):e981483.

Steiner S, Daniel C, Fischer A, Atreya I, Hirschmann S, Waldner M, Neumann H, Neurath M, Atreya R, Weigmann B. Cyclosporine a regulates pro-inflammatory cytokine production in ulcerative colitis. Arch Immunol Ther Exp (Warsz). 2015 Feb;63(1):53-63.

2014

Zenker S, Panteleev-Ivlev J, Wirtz S, Kishimoto T, Waldner MJ, Ksionda O, Tybulewicz VL, Neurath MF*, Atreya I*. A key regulatory role for Vav1 in controlling lipopolysaccharide endotoxemia via macrophage-derived IL-6. J Immunol. 2014 Mar 15;192(6):2830-6. (*Authors contributed equally).

2013

Neufert C, Becker C, Türeci Ö, Waldner MJ, Backert I, Floh K, Atreya I, Leppkes M, Jefremow A, Vieth M, Schneider-Stock R, Klinger P, Greten FR, Threadgill DW, Sahin U, Neurath MF. Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK. J Clin Invest. 2013 Apr;123(4):1428-43.

Böttcher JP, Schanz O, Wohlleber D, Abdullah Z, Debey-Pascher S, Staratschek-Jox A, Höchst B, Hegenbarth S, Grell J, Limmer A, Atreya I, Neurath MF, Busch DH, Schmitt E, van Endert P, Kolanus W, Kurts C, Schultze JL, Diehl L, Knolle PA. Liver-primed memory T cells generated under noninflammatory conditions provide anti-infectious immunity. Cell Rep. 2013 Mar 28;3(3):779-95.

Zenker S, Neurath MF, Atreya I. Targeted inhibition of Vav1 activity does not favour development of colitis-associated colon cancer. Inflamm Bowel Dis. 2013 Apr;19(5):E72-3.

Teichgräber U, Atreya I, Atreya R, Schwab M, Neurath MF. Infliximab treatment induces levels of the active azathioprine metabolite TGTP in Crohn's disease. Inflamm Bowel Dis. 2013 Mar-Apr;19(4):E54-5.

Ältere Publikationen

Atreya R, Zimmer M, Bartsch B, Waldner MJ, Atreya I, Neumann H, Hildner K, Hoffman A, Kiesslich R, Rink AD, Rau TT, Rose-John S, Kessler H, Schmidt J, Neurath MF. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages. Gastroenterology. 2011 Dec;141(6):2026-38.

Atreya I, Neurath MF. Understanding the delayed onset of action of azathioprine in IBD: are we there yet? Gut. 2009 Mar;58(3):325-6.

Atreya I, Neurath MF. Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications. Expert Rev Gastroenterol Hepatol. 2008 Feb;2(1):23-34.

Mudter J, Amoussina L, Schenk M, Yu J, Brüstle A, Weigmann B, Atreya R, Wirtz S, Becker C, Hoffman A, Atreya I, Biesterfeld S, Galle PR, Lehr HA, Rose-John S,  Mueller C, Lohoff M, Neurath MF. The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. J Clin Invest. 2008 Jul;118(7):2415-26.

Atreya I, Atreya R, Neurath MF. NF-kappaB in inflammatory bowel disease. J Intern Med. 2008 Jun;263(6):591-6.

Atreya I, Neurath MF. Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies. Expert Rev Anticancer Ther. 2008 Apr;8(4):561-72.

Atreya I, Schimanski CC, Becker C, Wirtz S, Dornhoff H, Schnürer E, Berger MR, Galle PR, Herr W, Neurath MF. The T-box transcription factor eomesodermin controls CD8 T cell activity and lymph node metastasis in human colorectal cancer. Gut. 2007 Nov;56(11):1572-8.

Hildner KM, Schirmacher P, Atreya I, Dittmayer M, Bartsch B, Galle PR, Wirtz S, Neurath MF. Targeting of the transcription factor STAT4 by antisensephosphorothioate oligonucleotides suppresses collagen-induced arthritis. Immunol. 2007 Mar 15;178(6):3427-36.

Siebler J, Wirtz S, Weigmann B, Atreya I, Schmitt E, Kreft A, Galle PR, Neurath MF. IL-28A is a key regulator of T-cell-mediated liver injury via the T-box transcription factor T-bet. Gastroenterology. 2007 Jan;132(1):358-71.

Atreya R, Atreya I, Neurath MF. Novel signal transduction pathways: analysis of STAT-3 and Rac-1 signaling in inflammatory bowel disease. Ann N Y Acad Sci. 2006 Aug;1072:98-113. Review.

Mudter J, Wirtz S, Weigmann B, Tiede I (now: Atreya I), Tubbe I, Kiesslich R, Galle PR, Lehr HA, Neurath MF. Crohn's-like colitis in a patient with immunodeficiency associated with a defect in expression of inducible costimulator. Dig Dis Sci. 2006 Apr;51(4):711-7.

Poppe D*, Tiede I* (now: Atreya I), Fritz G, Becker C, Bartsch B, Wirtz S, Strand D, Tanaka S, Galle PR, Bustelo XR, Neurath MF. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol. 2006 Jan 1;176(1):640-51. (*Authors contributed equally).

Tiede I (now: Atreya I), Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, Lehr HA, Wirtz S, Becker C, Atreya R, Mudter J, Hildner K, Bartsch B, Holtmann M, Blumberg R, Walczak H, Iven H, Galle PR, Ahmadian MR, Neurath MF. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003 Apr;111(8):1133-45.

 
 
  •  
  •  
  •  
  •  
  •  
 
 
 
Bitte tragen Sie Ihren Namen und gültige E-Mail-Adresse(n) ein!
X zum Schließen

Zusammenfassung